Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation

Heart

Volumn 85, Issue 2, 2001, Pages 133-142

  Brooks, N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEART ENZYME; NICORANDIL;

ANGIOCARDIOGRAPHY; BLOOD CLOT LYSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY RISK; ELECTROCARDIOGRAM; GOOD CLINICAL PRACTICE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION;

ACUTE DISEASE; ALGORITHMS; ANGINA, UNSTABLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; REFERRAL AND CONSULTATION; RISK ASSESSMENT;

EID: 0034763831     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Organisation to Assess Strategies for Ischaemic Syndromes (OASIS) Registry Investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation
2. New insights into the pathogenesis and prevention of acute coronary syndromes
3. Insights into the pathogenesis of acute ischemic syndromes
4. Insights into the pathophysiology of unstable coronary artery disease
5. Plaque fissuring: The cause of acute myocardial infarction, sudden death and unstable angina
6. Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after a first Q wave myocardial infarction
7. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
8. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial thrombolysis in myocardial ischemia
9. Low-molecular-weight heparin during instability in coronary artery disease
10. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Eragmin in unstable coronary artery disease study (FRIC)
11. Unstable angina. A classification
12. Early continuous ST segment monitoring in unstable angina: Prognostic value additional to the clinical characteristics and the admission electrocardiogram
13. Long-term prognosis in unstable angina. The importance of early risk stratification using continuous ST segment monitoring
14. The prognostic value of serum troponin T in unstable angina
15. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina
16. The role of cardiac troponin T and other new biochemical markers in evaluation and risk stratification of patients with acute chest pain syndromes
17. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary disease
18. Emergency room triage of patients with acute chest pain by means of rapid testing for troponin T or I
19. Cardiac troponin T levels for risk stratification in acute myocardial ischemia
20. Cardiac-specific troponin levels to predict the risk of mortality in patients with acute coronary syndromes
21. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
22. Prognosis of medically stabilized unstable angina pectoris with a negative exercise test
23. Unstable angina outcomes according to clinical presentation
24. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease
25. Non-invasive risk stratification within 48 hours of hospital admission in patients with unstable coronary artery disease
26. Relative contributions of a single admission 12-lead electrocardiogram and early 24-hour continuous electrocardiograph monitoring for early risk stratification in patients with unstable coronary artery disease
27. Prognostic value of the admission electrocardiogram in acute coronary syndromes
28. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
29. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris
30. Prognostic role of troponin T versus troponin I in unstable angina perctoris for cardiac events with meta-analysis comparing published studies
31. mass, myosin light chain 1, and myoglobin in the early in-hospital triage of "high risk" patients with chest pain
32. A clinical trial of a chest pain observation unit for patients with unstable angina
33. Costs of an emergency department-based diagnostic protocol vs hospitalisation in patiens with chest pain. A randomised controlled trial
34. An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: Results of a randomized study (ROMIO)
35. Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients
36. Emergency cardiac stress testing in the evaluation of emergency department patients with atypical chest pain
37. A 'same day' direct-access chest pain clinic: Improved management and reduced hospitalization
38. Outcome from a rapid-assessment chest pain clinic
39. Should we establish chest pain observation units in the UK? A systematic review and critical appraisal of the literature
40. Long-term (10 years) prognostic value of a normal thallium-201 myocardial exercise scintigraphy in patients with coronary artery disease documented by angiography
41. Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms
42. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and predischarge exercise tests
43. Prognostic significance of a fixed thallium defect one to six months after onset of acute myocardial infarction or unstable angina. Multicentre myocardial ischemia research group
44. Dipyridamole technetium 99m sestamibi myocardial tomography as an independent predictor of cardiac event-free survival after ischaemic events
45. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris
46. Prognostic value of predischarge dipyridamole technetium sestamibi myocardial tomography in medically treated patients with unstable angina
47. Selection bias in the management of unstable angina
48. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris
49. Risk stratification of patients with medically treated unstable angina using exercise echocardiography
50. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on coronary angiography)
51. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
52. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
53. Aspirin, heparin, or both to treat acute unstable angina
54. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
55. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease
56. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in myocardial infarction (TIMI) 11b trial
57. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11b-ESSENCE meta-analysis
58. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (fraxiparine in ischaemic syndrome)
59. Long-term low-molecular-weight heparin in unstable coronary artery disease. FRISC II prospective randomised multicentre study
60. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
61. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
62. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation
63. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIa receptor in high risk coronary angioplasty
64. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
65. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
66. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
67. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
68. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
69. Comparing trials of glycoprotein IIb/IIIa receptor antagonists
70. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
71. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
72. Patients with suspected myocardial infarction who present with ST depression
73. Thrombolytic therapy for unstable angina
74. Intravenous nitroglycerin in refractory unstable angina pectoris
75. Intravenous nitroglycerin for rest angina: Potential pathophysiologic mechanisms of action
76. Intravenous nitroglycerin for the treatment of angina at rest not responsive to standard nitrate therapy
77. Intravenous nitroglycerin in unstable angina
78. Relief of refractory angina with continuous intravenous infusion of nitroglycerin
79. Limitations of continuous intravenous nitroglycerin in patients with refractory angina at rest
80. Intravenous nitroglycerin for spontaneous angina: A short term, prospective, randomised trial
81. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: A prospective randomised trial
82. Buccal versus intravenous nitroglycerin in unstable angina pectoris
83. Nifedipine and conventional therapy for unstable angina pectoris: A randomised, double-blind comparison
84. Early treatment of unstable angina in the coronary care unit: A randomised, double-blind, placebo controlled comparison of recurrent ischemia in patient treated with nifedipine or metoprolol or both
85. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris. A randomised, double-blind, placebo controlled trial
86. Comparison of short-term efficacy of diltiazem and propranolol in unstable angina at rest - Randomised trial in 70 patients
87. Nifedipine in unstable angina: A double-blind randomised trial
88. Cardioprotection by opening of the KATP channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomised study with nicorandil
89. Overview of results of randomised clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification
90. Diltiazem and reinfarction in patients with non-Q wave myocardial infarction: Results of a double-blind, randomised, multicenter trial
91. The effect of diltiazem on mortality and reinfarction after myocardial infarction
92. Diltiazem increases late-onset congestive heart failure in post infarction patients with early reduction in ejection fraction
93. A controlled trial of verapamil in patients after acute myocardial infarction: Results of the calcium antagonist reinfarction Italian study (CRIS)
94. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II - DAVIT II)
95. ACC/AHA guidelines for coronary artery bypass graft surgery: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1991 guidelines for coronary artery bypass graft surgery)
96. A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease
97. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery
98. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration co-operative study
99. Medical compared with surgical management of unstable angina. 5 Year mortality and morbidity in the Veterans Administration study
100. Veterans Administration co-operative study for treatment of patients with unstable angina. Results in patients with abnormal left ventricular function
101. Coronary artery surgery improves survival in high-risk unstable angina. Results of a Veterans Administration co-operative study with an 8 year follow-up
102. Unstable angina pectoris: National co-operative study group to compare surgical and medical therapy
103. Determinants of operative mortality and long term survival in patients with unstable angina
104. One year results of the thrombolysis in myocardial infarction (TIMI) IIIb trial: A randomised comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative management strategies in unstable angina and non-Q-wave myocardial infarction
105. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
106. A prospective randomised trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial
107. Invasive versus conservative management of unstable angina and non-Q-wave myocardial infarction: A meta-analysis
108. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study
109. An early invasive strategy is associated with decreased mortality: GUSTO IIb trial
110. Contemporary approach to management of unstable angina
111. Management of unstable coronary artery disease
112. Normal coronary angiograms: Financial victory from the brink of clinical defeat?
113. Limitations of the Parsonnet score for measuring risk stratified mortality in the north west of England
114. Multi-centre validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery
115. A model that predicts morbidity and mortality after coronary artery bypass graft surgery
116. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease
117. Assessing the outcome of coronary artery bypass graft surgery: How many risk factors are enough
118. Coronary artery bypass grafting: The Society of Thoracic Surgeons National Database Experience
119. Initial report of the Veterans Administration preoperative risk assessment study for cardiac surgery
120. Death on the waiting list for coronary artery surgery
121. Waiting time and prioritisation for coronary artery bypass surgery in New Zealand
122. Determinants for early mortality in patients awaiting coronary artery bypass graft surgery: A case control study
123. Joint British recommendations on prevention of coronary heart disease in clinical practice
124. British Hypertension Society guidelines for hypertension management 1999: A summary
125. Guidelines for management of hypertension: Report of the Third Working Party of the British Hypertension Society